title: The clinical care of the HIV-1-infected infant.
abstract: Despite well-established strategies to decrease the mother-to-child transmission of HIV-1, new perinatal infections continue to occur globally, reflecting marked disparities in access to health care. Once HIV-1 infection has been established in an infant, the combination of early initiation of antiretroviral therapy and prophylaxis against Pneumocystis jiroveci pneumonia is paramount to reducing disease progression. This article reviews the recommendations and evidence for the treatment of HIV-1-infected infants.
authors.affiliation: Division of Pediatric Infectious Diseases, Department of Pediatrics, Children's Healthcare of Atlanta, Emory University, 2015 Uppergate Drive, Suite 500, Atlanta, GA 30322, USA.
authors.forename: Andres F
authors.initials: AF
authors.lastname: Camacho-Gonzalez
authors.forename: Allison C
authors.initials: AC
authors.lastname: Ross
authors.forename: Rana
authors.initials: R
authors.lastname: Chakraborty
mesh_terms: D044966:Anti-Retroviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use; D001942:Breast Feeding / Q000009:adverse effects; D002657:Child Development; D018450:Disease Progression; D015658:HIV Infections / Q000188:drug therapy* / Q000503:physiopathology; D015497:HIV-1; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D045363:Pneumocystis carinii; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*; D011159:Population Surveillance; D014611:Vaccination
chemical_list: D044966:Anti-Retroviral Agents; D001500:BCG Vaccine